MP-101 is under clinical development by Mitochon Pharmaceuticals and currently in Phase II for Primary Progressive Multiple Sclerosis (PPMS). According to GlobalData, Phase II drugs for Primary Progressive Multiple Sclerosis (PPMS) have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how MP-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MP-101 is under development for the treatment of Huntington’s disease, optic neuritis, Duchenne muscular dystrophy (DMD), secondary progressive multiple sclerosis (SPMS) and primary progressive multiple sclerosis (PPMS), amyotrophic lateral sclerosis and Parkinson’s disease. It is a small molecule and administered orally. The drug candidate is a prodrug of dinitrophenol (DNP).
The drug candidate was also under development for the treatment of Battens disease, Rett syndrome and burn victims and refractory epilepsy.
Mitochon Pharmaceuticals overview
Mitochon Pharmaceuticals (Mitochon Pharma) operates as a biotech company that develops drugs for neurodegenerative and neuromuscular diseases. The company’s pipeline products comprise mitochondrial modulators such as MP-101, MP-201 and MP-301. It targets diseases such as batten disease, stroke, huntington’s, duchenne muscular dystrophy, alzheimer’s, parkinson disease and severe burns. Mitochon Pharma’s MP101 preserves brain volume, medium spiny neurons and general neurons. The company also offers drugs for metabolic disorders due to over-nutrition such as diabetes, obesity and non-alcoholic steatohepatitis; and other diseases associated with high cellular stress. It undertakes clinical research to develop disease modifying therapies. Mitochon Pharma is headquartered in Whitpain, Pennsylvania, the US.
For a complete picture of MP-101’s drug-specific PTSR and LoA scores, buy the report here.